An F876l mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide)

Cancer Discovery

Volumn 3, Issue 9, 2013, Pages 1030-1043

  Korpal, Manav ^a   Korn, Joshua M ^a   Gao, Xueliang ^b   Rakiec, Daniel P ^a   Ruddy, David A ^a   Doshi, Shivang ^a   Yuan, Jing ^a   Kovats, Steve G ^a   Kim, Sunkyu ^a   Cooke, Vesselina G ^a   Monahan, John E ^a   Stegmeier, Frank ^a   Roberts, Thomas M ^b   Sellers, William R ^a   Zhou, Wenlai ^a   Zhu, Ping ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; ENZALUTAMIDE; KALLIKREIN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; F876L GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC RESISTANCE; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MUTATION; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SEQUENCE ANALYSIS, DNA;

EID: 84885214146     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0142     Document Type: Article

References (30)

1. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70: 745-754.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
4. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-1503.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
7. Kim W, Ryan CJ. Androgen receptor directed therapies in castrationresistant metastatic prostate cancer. Curr Treat Options Oncol 2012; 13: 189-200.
8. Wiederschain D, Chen L, Johnson B, Bettano K, Jackson D, Taraszka J, et al. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol 2007; 27: 4968-4979.
9. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
10. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11: 450-459.
11. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 1383-1388.
12. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-540.
13. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-153.
14. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124: 615-629.
15. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153-158.
16. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2013; 2: e00499.
17. Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP, et al. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer 2012; 19: 1-12.
18. Rader JA, Hart L, Russell M, Nakazawa M, Belcastro L, Martinez D, et al. CDK4/CDK6 inhibition is potently active in a defi nable subset of human neuroblastomas [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr 2744.
19. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001; 61: 4112-4121.
20. Kelly WK, Scher HI. Prostate specifi c antigen decline after antiandrogen withdrawal: the fl utamide withdrawal syndrome. J Urol 1993; 149: 607-609.
21. Small EJ, Carroll PR. Prostate-specifi c antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408-410.
22. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 91: 3-12
23. Huan SD, Gerridzen RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632-634.
24. Sella A, Flex D, Sulkes A, Baniel J. Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 1998; 52: 1091-1093.
25. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to 2nd generation anti-androgens enzalutamide and ARN-509. Cancer Discov 2013 Jun 18. [Epub ahead of print]
26. Gao W. Peptide antagonist of the androgen receptor. Curr Pharm Des 2010; 16: 1106-1113.
27. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-546.
28. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6: e001
29. Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene 2013 May 27. [Epub ahead of print]
30. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, et al. Genomic strategy for targeting therapy in castrationresistant prostate cancer. J Clin Oncol 2009; 27: 2022-2029.